Ingevity Corporation NGVT recorded profits of $59.8 million or $1.54 per share in second-quarter 2022, up from a profit of $44.3 million or $1.10 in the year-ago quarter.
Excluding one-time items, adjusted earnings in the quarter were $1.73 per share, up from $155 a year ago. The figure topped the Zacks Consensus Estimate of $1.68.
The company’s revenues rose around 17% year over year to a record $419.9 million in the quarter, beating the Zacks Consensus Estimate of $406.5 million. It benefited from actions to increase prices, which helped it offset inflationary cost pressures.
Ingevity Corporation Price, Consensus and EPS Surprise
Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation Quote
The Performance Chemicals division generated revenues of $297.5 million in the reported quarter, rising around 28% year over year. Sales rose around 21% in Engineered Polymers while sales in Industrial Specialties went up roughly 38%.
Revenues in the Performance Materials unit fell around 3% year over year to $122.4 million. Sales of activated carbon products were hurt by reduced automotive production due to the pandemic-related shutdowns in China and its impacts across the rest of the Asia-Pacific region.
Ingevity ended the quarter with cash and cash equivalents of $131.3 million, down around 44% year over year. Long-term debt was $1,176.2 million, down roughly 7% year over year.
Operating cash flow was $90.5 million for the reported quarter, up around 38% year over year.
The company reaffirmed its sales guidance for 2022 in the band of $1.525-$1.65 billion and adjusted EBITDA outlook in the range of $430-$470 million.
Shares of Ingevity have declined 14.6% in a year against a 18.4% decline of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Ingevity currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks worth considering in the basic materials space include Cabot Corporation CBT, Sociedad Quimica y Minera de Chile S.A. SQM and Albemarle Corporation ALB.
Cabot, currently carrying a Zacks Rank #1 (Strong Buy), has an expected earnings growth rate of 22.5% for the current fiscal year. The Zacks Consensus Estimate for CBT's earnings for the current fiscal has been revised 0.8% upward in the past 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cabot’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 16.2%. CBT has gained around 34% over a year.
Sociedad has a projected earnings growth rate of 513.7% for the current year. The Zacks Consensus Estimate for SQM’s current-year earnings has been revised 57.8% upward in the past 60 days.
Sociedad’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, the average being 28.2%. SQM has gained roughly 82% in a year. The company sports a Zacks Rank #1.
Albemarle has a projected earnings growth rate of 231.4% for the current year. The Zacks Consensus Estimate for ALB's current-year earnings has been revised 3.6% upward in the past 60 days.
Albemarle’s earnings beat the Zacks Consensus Estimate in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 24.2%, on average. ALB has gained around 3% in a year and currently carries a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Albemarle Corporation (ALB) : Free Stock Analysis Report
Sociedad Quimica y Minera S.A. (SQM) : Free Stock Analysis Report
Cabot Corporation (CBT) : Free Stock Analysis Report
Ingevity Corporation (NGVT) : Free Stock Analysis Report
To read this article on Zacks.com click here.